文献速递炎症性肠病

瑞典IBD质量登记队列研究:抗TNF药物生存预测因素比较

Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.
PubMed 文献 · Aliment Pharmacol Ther · 2021-07-19

基于瑞典IBD质量登记(SWIBREG)955例生物制剂初治患者,采用倾向性评分匹配比较一线抗TNF药物生存至多3年。克罗恩病中英夫利西单抗因缺乏/失去应答的停药率为32% vs 阿达木单抗16%,英夫利西单抗停药风险更高(aHR=1.96)。溃疡性结肠炎中两者停药率相近(40% vs 37%)。

要点

  • 克罗恩病中英夫利西单抗因缺乏/失去应答的停药率高于阿达木单抗(32% vs 16%)。
  • 克罗恩病中英夫利西单抗(vs阿达木单抗)与更高的停药率相关(aHR=1.96)。
  • 3个月时CRP正常化与更低的停药率相关(克罗恩病aHR=0.40,UC aHR=0.39)。

核心结论

  • 对患者进行临床特征刻画可能有助于抗TNF治疗决策。
  • 克罗恩病中英夫利西单抗(vs阿达木单抗)药物生存始终更短,提示两药可能存在差异。

研究设计与样本

  • 基于瑞典IBD质量登记(SWIBREG)的队列研究,纳入生物制剂初治患者N=955。
  • 采用倾向性评分匹配,比较至多3年随访的药物生存。
  • 使用Cox回归估计调整风险比(aHR)及95%置信区间(CI)。

主要发现

  • 克罗恩病中因缺乏/失去应答的停药率:英夫利西单抗32%[95%CI=26%-38%],阿达木单抗16%[95%CI=11%-21%]。
  • 克罗恩病中英夫利西单抗(vs阿达木单抗)aHR=1.96[95%CI=1.20-3.21],结肠病变(L2 vs 无L2)aHR=2.17[95%CI=1.26-3.75],3个月CRP正常化aHR=0.40[95%CI=0.19-0.81]。
  • 从阿达木单抗转换为英夫利西单抗(vs 反向转换)的患者停药更早(P=0.04)。
  • 合并使用免疫调节剂与更低的药物不良反应介导停药率相关(aHR=0.46[95%CI=0.28-0.77]),部分由更少的输注反应解释(aHR=0.27[95%CI=0.08-0.89])。
  • 溃疡性结肠炎中因缺乏/失去应答的停药概率:英夫利西单抗40%[95%CI=33%-47%],阿达木单抗37%[95%CI=21%-53%];病程≥10年aHR=0.25[95%CI=0.10-0.58],3个月CRP正常化aHR=0.39[95%CI=0.18-0.84]。

临床怎么用

  • 克罗恩病中选择阿达木单抗可能较英夫利西单抗获得更长的药物生存。
  • 合并使用免疫调节剂可降低药物不良反应介导的停药风险。
  • 3个月时CRP正常化提示更低的停药风险,可用于治疗监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether long-term effectiveness differs between anti-tumour necrosis factor (anti-TNF) agents is unknown. AIMS: To examine drug survival of first-line anti-TNF agents and identify predictors of discontinuation. To reduce channelling bias, we also compared drug survival of the second anti-TNF. METHODS: Biologic-naïve patients (N = 955) recorded in the Swedish IBD Quality Register (SWIBREG) were examined. We used propensity score matching, comparing drug survival over up to three years of follow-up. Cox regression estimated adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). RESULTS: In Crohn's disease, discontinuation because of lack/loss of response was 32% [95%CI = 26%-38%] for infliximab versus 16% [95%CI = 11%-21%] for adalimumab. Infliximab [vs adalimumab; aHR = 1.96; 95%CI = 1.20-3.21] and colonic disease (L2) [vs no L2; aHR = 2.17; 95% CI = 1.26-3.75] were associated with higher discontinuation rates, whereas normalised CRP at three months [aHR = 0.40; 95% CI = 0.19-0.81] with a lower rate. Consistently, patients who switched from adalimumab to infliximab (vs infliximab to adalimumab) had earlier discontinuation (P = 0.04). Concomitant use of immunomodulators was associated with a lower adverse drug reaction-mediated discontinuation rate [aHR = 0.46; 95% CI = 0.28-0.77], in part explained by fewer infusion reactions [aHR = 0.27; 95% CI = 0.08-0.89]. In ulcerative colitis, the probability of discontinuation because of lack/loss of response was 40% [95% CI = 33%-47%] for infliximab versus 37% [95% CI = 21%-53%] for adalimumab. Disease duration ≥10 years [aHR = 0.25; 95% CI = 0.10-0.58] and normalised CRP after three months [aHR = 0.39; 95% CI = 0.18-0.84] were associated with lower discontinuation rates. CONCLUSIONS: Clinical characterisation of patients may aid decision-making on anti-TNF treatment. The consistently shorter drug survival for infliximab (vs adalimumab) in Crohn's disease, suggests a potential difference between the two drugs.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Visuri I, Eriksson C, Olén O, et al. Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. Aliment Pharmacol Ther. 2021. PMID: 34286871. doi:10.1111/apt.16525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。